Summary of GRI Bio Conference Call Company Overview - GRI Bio is a clinical-stage biotech company focused on developing NKT cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [2][20] - The company has a focused pipeline with its lead program GRI-0621 currently in a Phase 2A study for idiopathic pulmonary fibrosis (IPF) [2][20] Key Programs and Clinical Studies - GRI-0621 is in a Phase 2A study for IPF, with top-line data expected later this month [2][7] - A second asset, GRI-0803, is focused on systemic lupus erythematosus and is expected to enter clinical studies next year [3][19] - GRI Bio has a pipeline of approximately 500 proprietary compounds for future development [3] Mechanism of Action - GRI Bio's technology aims to regulate the adaptive and innate immune systems, particularly through the modulation of NKT cells [3][4] - NKT cells play a crucial role in mediating crosstalk between the adaptive and innate immune systems, which is significant in diseases like IPF [4] Clinical Data and Efficacy - Preliminary data from GRI-0621 shows positive interim results after two and six weeks of therapy [7][12] - The drug has demonstrated significant reductions in fibrosis in various animal models compared to nintedanib, a current treatment for IPF [9][10] - GRI-0621 is a once-a-day oral formulation with extensive safety data from over 1,700 patients [11][12] Market Opportunity - IPF is a rare, chronic disease with a median survival of 2-3 years and a high unmet need for effective therapies [11] - Current approved drugs for IPF generate approximately $4 billion annually but do not significantly improve mortality outcomes [11] Biomarker Analysis - The Phase 2 study includes extensive biomarker analysis to assess collagen formation and degradation, which are critical in understanding fibrosis [13][15] - Changes in collagen types indicate potential for inducing lung repair mechanisms, which is vital for IPF patients [16] Competitive Landscape - The company differentiates itself by targeting core biological mechanisms driving chronic inflammatory and fibrotic diseases [18] - There is a high unmet need in the lupus treatment space, with only two drugs approved in the last 50 years [19] Conclusion - GRI Bio is positioned to create significant value for shareholders and improve treatment options for patients with chronic diseases [20]

Core Viewpoint - The research highlights the immune-regulating properties of Zeaxanthin, a nutrient found in leafy vegetables and corn, which enhances CD8+ T cell function and improves anti-tumor immunity, indicating its potential as a dietary supplement in cancer therapy [3][10]. Group 1: Research Findings - Zeaxanthin is identified as an immune modulator that enhances the function of CD8+ effector T cells, thereby increasing anti-tumor immunity [3][10]. - Oral supplementation of Zeaxanthin improves the efficacy of anti-PD-1 immune checkpoint inhibitors and enhances the cytotoxicity of TCR-engineered CD8+ T cells against tumor cells [9][10]. - The study utilized a "blood nutrient" library to identify dietary nutrients that influence CD8+ T cell function, revealing that trans-18:1 fatty acid (TVA) also promotes CD8+ T cell activity and response to immunotherapy [6][8]. Group 2: Mechanisms of Action - Zeaxanthin enhances T cell receptor (TCR) signaling on CD8+ T cells, improving their functional response [9][10]. - The research indicates that the structural isomer Lutein does not exhibit the same immune-enhancing effects as Zeaxanthin, underscoring the unique properties of Zeaxanthin [8][10]. - The findings suggest that dietary components can play a significant role in modulating immune responses, particularly in the context of cancer treatment [5][12].

来源：新浪财经-鹰眼工作室 2025年8月26日，上海复星医药（集团）股份有限公司发布公告称，其控股子公司复星医药产业与Sitala 达成《许可协议》。复星医药产业授予Sitala在除中国（包括港澳台地区）外的全球范围及人类、动物 疾病的诊断和治疗领域，开发、生产及商业化FXS6837及含有该活性成分产品的权利。同时，复星医药 产业（或其指定关联方）可以零对价获得价值500万美元的Sitala的股份，预计对Sitala的持股比例不超 过10%（全面摊薄后）。 许可产品情况 FXS6837是复星医药集团拥有自主知识产权的小分子抑制剂，拟用于免疫调节领域相关疾病的治疗。截 至2025年8月26日，FXS6837的相关适应症于中国境内处于II期临床试验阶段。截至2025年7月，集团现 阶段针对该在研药品累计研发投入约为人民币1.20亿元（未经审计）。根据IQVIA MIDASTM最新数 据，2024年，全球范围内用于治疗相关疾病的主要药品销售额合计约为38亿美元。 不过，该合作也存在一定风险。许可产品在许可区域的临床、注册、生产、销售等需得到相关监管机构 批准，临床试验能否完成以及能否获得上市批准存在不确定性。开发 ...

Group 1 - Heptagon Pharma announced the latest progress in its core patent rights protection, with the National Intellectual Property Administration maintaining the validity of its "combination molecule" patent, which involves the use of transgenic animals to produce fully human heavy chain antibodies (HCAb) [1] - The "combination molecule" patent is central to Heptagon Pharma's Harbour Mice® platform, which has established collaborations with several well-known pharmaceutical companies globally, indicating significant commercial value [1] Group 2 - Yunnan Baiyao's JZ-14 capsule, a first-in-class small molecule immunomodulator developed by its subsidiary, has received clinical trial approval, showing significant immunomodulatory and anti-proliferative activity in ulcerative colitis and various tumor models [2] - Successful clinical translation of JZ-14 could fill a gap in the immunomodulation field and expand Yunnan Baiyao's presence in chemical drug innovation [2] Group 3 - Rongchang Bio's product, Taihetai (RC18), has received orphan drug designation from the European Commission for the treatment of myasthenia gravis, which provides various policy supports including scientific advice on development plans and a ten-year market exclusivity post-approval [3] Group 4 - Merck's Clesrovimab (MK-1654) injection application is proposed for priority review by the National Medical Products Administration, aimed at preventing lower respiratory tract infections caused by RSV in newborns and infants entering or born during the RSV season [4] - Clesrovimab's long-acting protective characteristics may alter the current RSV prevention landscape, necessitating attention to its competitive differentiation from vaccines and pricing strategies [4]

Core Viewpoint - The study reveals that Itaconate, contrary to its traditional anti-inflammatory perception, promotes inflammatory responses in tissue-resident alveolar macrophages, exacerbating acute lung injury [2][9]. Group 1: Effects of Itaconate - Itaconate enhances the production of pro-inflammatory cytokines and activates the NLRP3 inflammasome in alveolar macrophages [4][7]. - Pre-treatment with Itaconate worsens LPS-induced lung tissue damage, while knocking out ACOD1 significantly improves survival rates in acute lung injury mouse models [2][6]. Group 2: Comparison with Bone Marrow-Derived Macrophages - The response of bone marrow-derived macrophages (BMDM) to Itaconate is opposite to that of tissue-resident alveolar macrophages, indicating the critical role of the pulmonary microenvironment in shaping macrophage immune metabolism [5][10]. Group 3: Itaconate Derivatives - Unlike natural Itaconate, its derivatives, dimethyl itaconate (DI) and 4-octyl itaconate (4OI), can inhibit the inflammatory response in alveolar macrophages [4][7]. Group 4: Implications for Clinical Treatment - The findings suggest that further research is necessary before considering Itaconate for clinical applications in treating inflammatory diseases, given its unexpected pro-inflammatory role in tissue-resident alveolar macrophages [9][10].

在大健康产业蓬勃发展的当下，梅花鹿产品凭借其独特的滋补与药用价值，在市场上愈发受到青睐。尊 禧鹿生物科技研究（湖北）院应运而生，专注于梅花鹿产品的全方位研究，尤其在质量检测与成分分析 领域成果斐然，为梅花鹿产业的健康发展筑牢根基。 深入剖析：解密成分奥秘 梅花鹿产品成分复杂，蕴含多种对人体有益的物质。为了深入了解这些成分，挖掘其潜在价值，尊禧鹿 生物科技研究（湖北）院组建了专业的研发团队，团队成员涵盖生物化学、药学、营养学等多领域专 家。 在对鹿茸的研究中，科研人员运用现代分离技术，先通过高效液相色谱（HPLC）对鹿茸提取物进行初 步分离，将性质相近的成分进行分组。随后，借助制备型高效液相色谱进一步提纯，获取高纯度的目标 成分。再通过质谱（MS）技术，精确测定各成分的分子量，并结合核磁共振（NMR）波谱，确定其化 学结构与组成。经过大量实验，研究发现，每 100 克鹿茸中，含有氨基酸总量高达 50 - 60 克，其中包 含人体必需的 8 种氨基酸；多肽含量约为 10 - 15 克，且不同分子量的多肽具有不同生物活性。此外， 还富含钙、磷、镁等矿物质以及小分子代谢物 "尿苷" 等。其中，"尿苷" 在动物实验中表 ...

在儿童健康领域，过敏性鼻炎合并腺样体肥大已成为一个不容忽视的疾病。其不仅影响患儿的呼吸质 量，还可能引发腺样体面容、生长发育迟缓等一系列问题。 如今，关于儿童过敏性鼻炎合并腺样体肥大的治疗，一种名为京生·脾氨肽口服溶液的双向免疫调节剂 正引发广泛关注。凭借其独特的双向免疫调节机制，该产品不仅显著改善了过敏性鼻炎合并腺样体肥大 患儿的症状，更从根源上阻断了疾病发展的恶性循环，为无数家庭带来了希望。 疾病之困：过敏性鼻炎与腺样体肥大的双重挑战 过敏性鼻炎是儿童常见疾病之一，其发病率在全球范围内呈上升趋势。而当过敏性鼻炎合并腺样体肥大 时，病情往往更加复杂和棘手。 腺样体位于鼻咽部，是鼻咽部淋巴组织的一部分，在过敏反应刺激下，腺样体可能发生病理性肥大，导 致鼻咽部阻塞，进而引发一系列症状，如鼻塞、流涕、睡眠打鼾、张口呼吸等。更为严重的是，过敏性 鼻炎与腺样体肥大之间可能形成恶性循环。过敏性鼻炎引起的鼻黏膜肿胀和分泌物增多可能刺激腺样体 进一步肥大，而肥大的腺样体又可能加重鼻咽部阻塞，使过敏性鼻炎症状更加难以控制。这种恶性循环 不仅影响了患儿的生活质量，还可能对患儿的生长发育和心理健康造成长期影响。 京生·脾氨肽口服 ...